PCMA Supports E-Prescribing Legislation to Combat Opioid Crisis
WASHINGTON, April 25, 2018 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) released the following statement on the House Energy and Commerce Health Subcommittee's consideration of H.R. 3528 / S. 2460 the Every Prescription Conveyed Securely Act, which requires electronic prescribing (e-prescribing) for controlled substances in Medicare Part D.
"E-prescribing helps ensure each prescription is written by a legitimate provider and filled at a legitimate pharmacy. This bill is an important solution that attacks the opioid epidemic by preventing doctor shopping and drugstore and reducing costs inflicted on patients and taxpayers."
A new study by Health IT Now's Opioid Safety Alliance finds H.R. 3528 would reduce federal spending $13 billion over 10 years. This is consistent with a separate study by Visante and Point-of-Care Partners that finds mandatory e-prescribing of controlled substances in Medicare would save the federal government more than $2 billion annually ? due to decreased treatment costs and greater efficiencies in physician offices and pharmacies, among other factors.
A broad coalition supports passage of H.R. 3528, including:
Pharmaceutical Care Management Association
CVS Health
Express Scripts
Magellan Health
Prime Therapeutics
Albertsons Companies
America's Health Insurance Plans
AmerisourceBergen
Association for Accessible Medicines
College of Healthcare Information Management Executives
Healthcare Information and Management Systems Society
Health IT Now
Imprivata
National Coalition on Health Care
National Consumers League
National Association of Chain Drug Stores
National Community Pharmacists Association
Rite Aid
Surescripts
Walgreens
PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community. Aspire Health experienced a data security incident that may have involved personal and...